aluates Reports

$ 0.0

Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-3F11972

Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2022

BUY CHAPTERS

Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2025

Code: QYRE-Auto-3F11972

Report

January 2025

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bayer

Eisai Co Ltd

Zelgen

Cipla Ltd

Natco Pharma

Beacon Pharma

Yao Pharma

CSPC

Chiatai Tianqing

Simcere

Jiangxi Shanxiang

Hepatocellular Carcinoma Targeted Drug Market Size

The global market for Hepatocellular Carcinoma Targeted Drug was valued at US$ 977 million in the year 2024 and is projected to reach a revised size of US$ 1641 million by 2031, growing at a CAGR of 7.8% during the forecast period.

Hepatocellular Carcinoma Targeted Drug Market

The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Hepatocellular Carcinoma Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocellular Carcinoma Targeted Drug.

The Hepatocellular Carcinoma Targeted Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatocellular Carcinoma Targeted Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatocellular Carcinoma Targeted Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hepatocellular Carcinoma Targeted Drug Market Report

Report Metric	Details
Report Name	Hepatocellular Carcinoma Targeted Drug Market
Accounted market size in year	US$ 977 million
Forecasted market size in 2031	US$ 1641 million
CAGR	7.8%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Sorafenib Lenvatinib Regorafenib Other
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma, CSPC, CHIATAI Tianqing, Simcere
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatocellular Carcinoma Targeted Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hepatocellular Carcinoma Targeted Drug Market growing?

Ans: The Hepatocellular Carcinoma Targeted Drug Market witnessing a CAGR of 7.8% during the forecast period 2025-2031.

What is the Hepatocellular Carcinoma Targeted Drug Market size in 2031?

Ans: The Hepatocellular Carcinoma Targeted Drug Market size in 2031 will be US$ 1641 million.

Who are the main players in the Hepatocellular Carcinoma Targeted Drug Market report?

Ans: The main players in the Hepatocellular Carcinoma Targeted Drug Market are Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma, CSPC, CHIATAI Tianqing, Simcere

What are the Application segmentation covered in the Hepatocellular Carcinoma Targeted Drug Market report?

Ans: The Applications covered in the Hepatocellular Carcinoma Targeted Drug Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Hepatocellular Carcinoma Targeted Drug Market report?

Ans: The Types covered in the Hepatocellular Carcinoma Targeted Drug Market report are Sorafenib, Lenvatinib, Regorafenib, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Sorafenib

1.2.3 Lenvatinib

1.2.4 Regorafenib

1.2.5 Other

1.3 Market by Application

1.3.1 Global Hepatocellular Carcinoma Targeted Drug Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hepatocellular Carcinoma Targeted Drug Market Perspective (2020-2031)

2.2 Global Hepatocellular Carcinoma Targeted Drug Growth Trends by Region

2.2.1 Global Hepatocellular Carcinoma Targeted Drug Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hepatocellular Carcinoma Targeted Drug Historic Market Size by Region (2020-2025)

2.2.3 Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Region (2026-2031)

2.3 Hepatocellular Carcinoma Targeted Drug Market Dynamics

2.3.1 Hepatocellular Carcinoma Targeted Drug Industry Trends

2.3.2 Hepatocellular Carcinoma Targeted Drug Market Drivers

2.3.3 Hepatocellular Carcinoma Targeted Drug Market Challenges

2.3.4 Hepatocellular Carcinoma Targeted Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hepatocellular Carcinoma Targeted Drug Players by Revenue

3.1.1 Global Top Hepatocellular Carcinoma Targeted Drug Players by Revenue (2020-2025)

3.1.2 Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Players (2020-2025)

3.2 Global Hepatocellular Carcinoma Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hepatocellular Carcinoma Targeted Drug Revenue

3.4 Global Hepatocellular Carcinoma Targeted Drug Market Concentration Ratio

3.4.1 Global Hepatocellular Carcinoma Targeted Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Targeted Drug Revenue in 2024

3.5 Global Key Players of Hepatocellular Carcinoma Targeted Drug Head office and Area Served

3.6 Global Key Players of Hepatocellular Carcinoma Targeted Drug, Product and Application

3.7 Global Key Players of Hepatocellular Carcinoma Targeted Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hepatocellular Carcinoma Targeted Drug Breakdown Data by Type

4.1 Global Hepatocellular Carcinoma Targeted Drug Historic Market Size by Type (2020-2025)

4.2 Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Type (2026-2031)

5 Hepatocellular Carcinoma Targeted Drug Breakdown Data by Application

5.1 Global Hepatocellular Carcinoma Targeted Drug Historic Market Size by Application (2020-2025)

5.2 Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hepatocellular Carcinoma Targeted Drug Market Size (2020-2031)

6.2 North America Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025)

6.4 North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hepatocellular Carcinoma Targeted Drug Market Size (2020-2031)

7.2 Europe Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025)

7.4 Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size (2020-2031)

8.2 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2020-2025)

8.4 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hepatocellular Carcinoma Targeted Drug Market Size (2020-2031)

9.2 Latin America Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025)

9.4 Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size (2020-2031)

10.2 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025)

10.4 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer

11.1.1 Bayer Company Details

11.1.2 Bayer Business Overview

11.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Introduction

11.1.4 Bayer Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.1.5 Bayer Recent Development

11.2 Eisai

11.2.1 Eisai Company Details

11.2.2 Eisai Business Overview

11.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Introduction

11.2.4 Eisai Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.2.5 Eisai Recent Development

11.3 Zelgen

11.3.1 Zelgen Company Details

11.3.2 Zelgen Business Overview

11.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Introduction

11.3.4 Zelgen Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.3.5 Zelgen Recent Development

11.4 Cipla

11.4.1 Cipla Company Details

11.4.2 Cipla Business Overview

11.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Introduction

11.4.4 Cipla Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.4.5 Cipla Recent Development

11.5 Natco Pharma

11.5.1 Natco Pharma Company Details

11.5.2 Natco Pharma Business Overview

11.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Introduction

11.5.4 Natco Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.5.5 Natco Pharma Recent Development

11.6 BEACON Pharma

11.6.1 BEACON Pharma Company Details

11.6.2 BEACON Pharma Business Overview

11.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Introduction

11.6.4 BEACON Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.6.5 BEACON Pharma Recent Development

11.7 Jiangxi Shanxiang

11.7.1 Jiangxi Shanxiang Company Details

11.7.2 Jiangxi Shanxiang Business Overview

11.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Introduction

11.7.4 Jiangxi Shanxiang Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.7.5 Jiangxi Shanxiang Recent Development

11.8 Yao Pharma

11.8.1 Yao Pharma Company Details

11.8.2 Yao Pharma Business Overview

11.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Introduction

11.8.4 Yao Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.8.5 Yao Pharma Recent Development

11.9 CSPC

11.9.1 CSPC Company Details

11.9.2 CSPC Business Overview

11.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Introduction

11.9.4 CSPC Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.9.5 CSPC Recent Development

11.10 CHIATAI Tianqing

11.10.1 CHIATAI Tianqing Company Details

11.10.2 CHIATAI Tianqing Business Overview

11.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Introduction

11.10.4 CHIATAI Tianqing Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.10.5 CHIATAI Tianqing Recent Development

11.11 Simcere

11.11.1 Simcere Company Details

11.11.2 Simcere Business Overview

11.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Introduction

11.11.4 Simcere Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

11.11.5 Simcere Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bayer

Eisai Co Ltd

Zelgen

Cipla Ltd

Natco Pharma

Beacon Pharma

Yao Pharma

CSPC

Chiatai Tianqing

Simcere

Jiangxi Shanxiang

List of Tables

Table 1. Global Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Sorafenib

Table 3. Key Players of Lenvatinib

Table 4. Key Players of Regorafenib

Table 5. Key Players of Other

Table 6. Global Hepatocellular Carcinoma Targeted Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Hepatocellular Carcinoma Targeted Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Hepatocellular Carcinoma Targeted Drug Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region (2020-2025)

Table 10. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region (2026-2031)

Table 12. Hepatocellular Carcinoma Targeted Drug Market Trends

Table 13. Hepatocellular Carcinoma Targeted Drug Market Drivers

Table 14. Hepatocellular Carcinoma Targeted Drug Market Challenges

Table 15. Hepatocellular Carcinoma Targeted Drug Market Restraints

Table 16. Global Hepatocellular Carcinoma Targeted Drug Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Hepatocellular Carcinoma Targeted Drug Market Share by Players (2020-2025)

Table 18. Global Top Hepatocellular Carcinoma Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Targeted Drug as of 2024)

Table 19. Ranking of Global Top Hepatocellular Carcinoma Targeted Drug Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Targeted Drug Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Hepatocellular Carcinoma Targeted Drug, Headquarters and Area Served

Table 22. Global Key Players of Hepatocellular Carcinoma Targeted Drug, Product and Application

Table 23. Global Key Players of Hepatocellular Carcinoma Targeted Drug, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Hepatocellular Carcinoma Targeted Drug Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Type (2020-2025)

Table 27. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Type (2026-2031)

Table 29. Global Hepatocellular Carcinoma Targeted Drug Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Application (2020-2025)

Table 31. Global Hepatocellular Carcinoma Targeted Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Application (2026-2031)

Table 33. North America Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size by Country (2026-2031) & (US$ Million)

Table 48. Bayer Company Details

Table 49. Bayer Business Overview

Table 50. Bayer Hepatocellular Carcinoma Targeted Drug Product

Table 51. Bayer Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 52. Bayer Recent Development

Table 53. Eisai Company Details

Table 54. Eisai Business Overview

Table 55. Eisai Hepatocellular Carcinoma Targeted Drug Product

Table 56. Eisai Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 57. Eisai Recent Development

Table 58. Zelgen Company Details

Table 59. Zelgen Business Overview

Table 60. Zelgen Hepatocellular Carcinoma Targeted Drug Product

Table 61. Zelgen Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 62. Zelgen Recent Development

Table 63. Cipla Company Details

Table 64. Cipla Business Overview

Table 65. Cipla Hepatocellular Carcinoma Targeted Drug Product

Table 66. Cipla Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 67. Cipla Recent Development

Table 68. Natco Pharma Company Details

Table 69. Natco Pharma Business Overview

Table 70. Natco Pharma Hepatocellular Carcinoma Targeted Drug Product

Table 71. Natco Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 72. Natco Pharma Recent Development

Table 73. BEACON Pharma Company Details

Table 74. BEACON Pharma Business Overview

Table 75. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product

Table 76. BEACON Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 77. BEACON Pharma Recent Development

Table 78. Jiangxi Shanxiang Company Details

Table 79. Jiangxi Shanxiang Business Overview

Table 80. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product

Table 81. Jiangxi Shanxiang Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 82. Jiangxi Shanxiang Recent Development

Table 83. Yao Pharma Company Details

Table 84. Yao Pharma Business Overview

Table 85. Yao Pharma Hepatocellular Carcinoma Targeted Drug Product

Table 86. Yao Pharma Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 87. Yao Pharma Recent Development

Table 88. CSPC Company Details

Table 89. CSPC Business Overview

Table 90. CSPC Hepatocellular Carcinoma Targeted Drug Product

Table 91. CSPC Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 92. CSPC Recent Development

Table 93. CHIATAI Tianqing Company Details

Table 94. CHIATAI Tianqing Business Overview

Table 95. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product

Table 96. CHIATAI Tianqing Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 97. CHIATAI Tianqing Recent Development

Table 98. Simcere Company Details

Table 99. Simcere Business Overview

Table 100. Simcere Hepatocellular Carcinoma Targeted Drug Product

Table 101. Simcere Revenue in Hepatocellular Carcinoma Targeted Drug Business (2020-2025) & (US$ Million)

Table 102. Simcere Recent Development

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Hepatocellular Carcinoma Targeted Drug Picture

Figure 2. Global Hepatocellular Carcinoma Targeted Drug Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hepatocellular Carcinoma Targeted Drug Market Share by Type: 2024 VS 2031

Figure 4. Sorafenib Features

Figure 5. Lenvatinib Features

Figure 6. Regorafenib Features

Figure 7. Other Features

Figure 8. Global Hepatocellular Carcinoma Targeted Drug Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Hepatocellular Carcinoma Targeted Drug Market Share by Application: 2024 VS 2031

Figure 10. Hospital Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. Other Case Studies

Figure 13. Hepatocellular Carcinoma Targeted Drug Report Years Considered

Figure 14. Global Hepatocellular Carcinoma Targeted Drug Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Hepatocellular Carcinoma Targeted Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Hepatocellular Carcinoma Targeted Drug Market Share by Region: 2024 VS 2031

Figure 17. Global Hepatocellular Carcinoma Targeted Drug Market Share by Players in 2024

Figure 18. Global Top Hepatocellular Carcinoma Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Targeted Drug as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Targeted Drug Revenue in 2024

Figure 20. North America Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Hepatocellular Carcinoma Targeted Drug Market Share by Country (2020-2031)

Figure 22. United States Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Hepatocellular Carcinoma Targeted Drug Market Share by Country (2020-2031)

Figure 26. Germany Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Hepatocellular Carcinoma Targeted Drug Market Share by Region (2020-2031)

Figure 34. China Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Hepatocellular Carcinoma Targeted Drug Market Share by Country (2020-2031)

Figure 42. Mexico Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Hepatocellular Carcinoma Targeted Drug Market Share by Country (2020-2031)

Figure 46. Turkey Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Hepatocellular Carcinoma Targeted Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 50. Eisai Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 51. Zelgen Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 52. Cipla Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 53. Natco Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 54. BEACON Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 55. Jiangxi Shanxiang Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 56. Yao Pharma Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 57. CSPC Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 58. CHIATAI Tianqing Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 59. Simcere Revenue Growth Rate in Hepatocellular Carcinoma Targeted Drug Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Kidney Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38R2107

Fri Mar 14 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Radiotherapy Positioning Products Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34T16080

Fri Mar 14 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Radiation Oncology Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35A12535

Thu Mar 13 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Kidney Cancer Targeted Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24A14985

Thu Mar 13 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions